STAAR Surgical (STAA) Swings To Profit On China Rebound
STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, with net income of $8.1M. China sales more than doubled to $52.3M, now over half of total revenue. CEO Warren Foust outlined plans for growth. Global sales rose 6% excluding China, and gross margin improved to 74.5%. The company ended the quarter with $181.5M in cash and no debt.
How this was made
The 30-second read
Why it matters
The earnings beat and cash buildup suggest near‑term upside, but tariff and cost pressures create downside risk.
Market read
Microcap medical device stock with a significant earnings surprise and a China‑centric growth story.
What to watch
One‑time baseline adjustments and upcoming ERP costs may mask underlying profitability trends.
Background
STAAR Surgical (NASDAQ:STAA) posted its first profitable quarter after a loss in the same period a year earlier, driven by a sharp rebound in China sales.
Ticker impact
STAAR Surgical reported Q3 results with 111% sales growth and a $8.1M profit, driven by a China sales rebound.
Potential upside of 10‑15% if momentum sustains; downside risk if China growth stalls.
Revenue and profit surprise, cash strength, and expanding market share in China support a bullish view, while short‑interest and tariff headwinds temper confidence.
Market effects
Refractive surgery equipment sector may see renewed investor interest as STAAR's China rebound highlights growth potential.
China's ophthalmic market could attract more capital as STAAR gains share from laser‑based procedures.
Strong microcap earnings may influence risk‑on sentiment in niche medical device space.
Counterpoint
High short interest and tariff exposure could pressure the stock if China growth normalizes or margins compress.
Key entities
- ExecutiveWarren Foust
New CEO who outlined the China growth strategy.
